

Viridian Pharmaceuticals

Investment Teaser

Privately held specialty pharmaceutical company advancing transdermal 505(b)(2) drug programs across large therapeutic markets.

Headquartered in the USA, Viridian combines in-house formulation, limited scale GMP manufacturing, development and early-stage testing with an experienced external regulatory, clinical and manufacturing network. The portfolio spans CNS, cardiovascular, metabolic, oncology and autoimmune opportunities.



INDUSTRY

Specialty Pharma

HEADQUARTERS

US

PLATFORM

505(b)(2) TDS

PIPELINE

15+ reference APIs

COMPANY OVERVIEW

- Privately held specialty pharmaceutical company headquartered in the USA.
- Focused on transdermal 505(b)(2) product development across CNS, cardiovascular, metabolic, oncology and other therapeutic categories.
- All formulation, development and early-stage testing are conducted in-house, supported by specialized regulatory, clinical and manufacturing partners.

TRANSACTION OVERVIEW

- Seeking investment and strategic partnerships to advance clinical studies of select product opportunities.
- Stated opportunities include out-licensing of technology and partnering around individual pipeline assets.
- Additional capital to support advancing lead products through human Pharmacokinetics studies which have been derisked through animal PK studies, regulatory approval and manufacturing readiness.

INVESTMENT HIGHLIGHTS

- 01 Focused transdermal 505(b)(2) strategy**
Programs are built around developing transdermal systems for known APIs in approved oral formulations and transdermal delivery, and targeting differentiated dosing, adherence and product positioning.
- 02 Integrated formulation & development platform**
In-house transdermal formulation and early-stage testing and small-scale manufacturing, and are supported by external regulatory, clinical and manufacturing partners, enabling efficient advancement from feasibility through scale-up.
- 03 Diversified pipeline with lead readiness**
Portfolio spans multiple therapeutic areas, with at least five products, including Lurasidone, Guanfacine, Risperidone, Tofacitinib, Dapagliflozin and Tizanidine getting ready for clinicals and additional assets in preclinical / development.
- 04 Multiple investment & partnering pathways**
Company materials cite product investment, clinical partnerships and out-licensing of technology as core strategic opportunities.

SELECTED PORTFOLIO SNAPSHOT

Asset	Indication	Reference Brand	Current Status
Tofacitinib	Autoimmune conditions (RA/ PsA, UC etc.)	Xeljanz	Clinicals
Tizanidine	Muscle spasms	Zanaflex	Clinicals
Guanfacine	ADHD / hypertension	Intuniv / Tenex	Preclinical ready
Lenalidomide	Multiple myeloma	Revlimid	Development
Rivaroxaban	Anticoagulant	Xarelto	On hold - enhancer

PRODUCT / PLATFORM OVERVIEW

- Novel Monolithic drug-in-adhesive transdermal systems designed around known APIs and differentiated delivery profiles.
- Silicone, PIB and acrylic adhesive platforms plus chemical / peptide permeation enhancers broaden formulation flexibility.
- Formulations are built for commercial scalability and compatibility with standard manufacturing equipment.

DEVELOPMENT MODEL

- Viridian conducts formulation, development and early-stage testing internally for greater control and speed.
- Consultants and CRO partners provide deep transdermal, clinical and 505(b)(2) regulatory expertise.
- CMO relationships support clinical trial supply and commercial manufacturing readiness.

END MARKETS & FOOTPRINT

- Portfolio spans CNS / psychiatric, withdrawal, neurology, metabolic, cardiovascular, oncology and autoimmune indications.
- Source materials cite approx. \$91.4B of aggregate reference-product sales across selected products and an illustrative approx. \$9.1B 10% TDS opportunity.
- Headquarters and lab operations are based in Doylestown, PA within the PA Biotechnology Center.

KEY DIFFERENTIATORS

01 Patient-friendly delivery profile

Potential to bypass GI-related issues, smooth PK and simplify dosing relative to oral regimens for select molecules.

02 Flexible formulation chemistry

Silicone, PIB and acrylic systems plus permeation enhancers broaden API applicability across multiple therapeutic categories.

03 Built for scale-up

Standard-equipment compatibility, in-house R&D and CMO readiness support efficient program advancement.

04 IP & monetization optionality

Programs are screened for patent / proprietary protection and can be advanced through licensing, partnership or product-level investment.

Financial Forecast & NPV Overview

Viridian Pharmaceuticals | Investment Teaser

FORECAST SUMMARY

5-YR REVENUE (\$MM)

\$142.5

2026–2030 total sales

5-YR EBITDA (\$MM)

\$57.0

40% minimum EBITDA expectation model conversion

AGGREGATE NPV @ 10%

\$37.2

discounted EBITDA


2030 REVENUE (\$MM)

\$87.4

year-5 revenue run-rate

REVENUE PROJECTION (5 PRODUCTS)

5-year Sales & EBITDA of Viridian
US\$ million



PRODUCT-LEVEL NPV @ 10%

Product	Launch	2030 Sales (\$MM)	NPV (\$MM)
Tizanidine	2027	\$7.2	\$4.3
Lurasidone	2028	\$34.7	\$15.4
Risperidone	2028	\$9.5	\$4.2
Guanfacine	2028	\$9.5	\$4.2
Tofacitinib	2029	\$26.5	\$9.1
Total	—	\$87.4	\$37.2

NPV calculated from product EBITDA using the model's 40% EBITDA conversion and 10% discount rate.